Suven Life Sciences announces that the grant of one product patent from New Zealand and one product patent from Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034 and 2027 respectively.
The granted claims of the patents include the class of selective 5HT6 compounds and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia respectively.
''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' says Venkat Jasti, CEO of Suven.
Shares of the company gained Rs 3.85, or 2.04%, to trade at Rs 192.60. The total volume of shares traded was 39,414 at the BSE (10.21 a.m., Wednesday).